METIS TECHBIO-P Shares Surge Nearly 5% on Strategic AI Drug Development Alliance with Deerfield

Stock News06-01 10:22

METIS TECHBIO-P (07666) rose close to 5% in Hong Kong trading. At the time of writing, the stock was up 4.47%, trading at HK$15.44 with a turnover of HK$8.22 million.

The increase follows the company's announcement of a strategic alliance with the premier global health investment and innovation platform, Deerfield Management. The partnership aims to co-develop a new generation of in vivo protein therapeutics and immunotherapies, while jointly advancing the global commercialization of collaborative pipeline products.

Under the agreement, Deerfield will engage in in-depth collaboration on the global clinical development and commercial expansion initiatives related to METIS TECHBIO-P's proprietary AI-powered nano-delivery platform, NanoForge, its driven solutions, and core pipeline projects. This includes a leading T-cell engager (TCE) project, discovered and advanced to the pre-clinical candidate (PCC) stage by the company's in-house AiProtein platform.

Deerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191305063?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 10:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191305063","market":"fut","top_or_hot":-1,"title":"METIS TECHBIO-P Shares Surge Nearly 5% on Strategic AI Drug Development Alliance with Deerfield","media":"Stock News","content":"<p>METIS TECHBIO-P (07666) rose close to 5% in Hong Kong trading. At the time of writing, the stock was up 4.47%, trading at HK$15.44 with a turnover of HK$8.22 million.</p>\n<p>The increase follows the company's announcement of a strategic alliance with the premier global health investment and innovation platform, Deerfield Management. The partnership aims to co-develop a new generation of in vivo protein therapeutics and immunotherapies, while jointly advancing the global commercialization of collaborative pipeline products.</p>\n<p>Under the agreement, Deerfield will engage in in-depth collaboration on the global clinical development and commercial expansion initiatives related to METIS TECHBIO-P's proprietary AI-powered nano-delivery platform, NanoForge, its driven solutions, and core pipeline projects. This includes a leading T-cell engager (TCE) project, discovered and advanced to the pre-clinical candidate (PCC) stage by the company's in-house AiProtein platform.</p>\n<p>Deerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>METIS TECHBIO-P Shares Surge Nearly 5% on Strategic AI Drug Development Alliance with Deerfield</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMETIS TECHBIO-P Shares Surge Nearly 5% on Strategic AI Drug Development Alliance with Deerfield\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-01 10:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>METIS TECHBIO-P (07666) rose close to 5% in Hong Kong trading. At the time of writing, the stock was up 4.47%, trading at HK$15.44 with a turnover of HK$8.22 million.</p>\n<p>The increase follows the company's announcement of a strategic alliance with the premier global health investment and innovation platform, Deerfield Management. The partnership aims to co-develop a new generation of in vivo protein therapeutics and immunotherapies, while jointly advancing the global commercialization of collaborative pipeline products.</p>\n<p>Under the agreement, Deerfield will engage in in-depth collaboration on the global clinical development and commercial expansion initiatives related to METIS TECHBIO-P's proprietary AI-powered nano-delivery platform, NanoForge, its driven solutions, and core pipeline projects. This includes a leading T-cell engager (TCE) project, discovered and advanced to the pre-clinical candidate (PCC) stage by the company's in-house AiProtein platform.</p>\n<p>Deerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1191305063","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191305063","pubTimestamp":1780280541,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"METIS TECHBIO-P (07666) rose close to 5% in Hong Kong trading. At the time of writing, the stock was up 4.47%, trading at HK$15.44 with a turnover of HK$8.22 million. The increase follows the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","07666":"剂泰科技-P","BK1161":"生物科技","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","ARTY":"ISHARES FUTURE AI & TECH ETF","AGIX":"通用人工智能 ETF-AGIX","AIPO":"Defiance AI and Power Infrastructure ETF"},"translate_title":"METIS TECHBIO-P与Deerfield结成人工智能药物开发战略联盟，股价飙升近5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIX":1,"CHAT":1,"VXUS":1,"07666":1,"AIPO":1,"ARTY":1},"content_text":"METIS TECHBIO-P (07666) rose close to 5% in Hong Kong trading. At the time of writing, the stock was up 4.47%, trading at HK$15.44 with a turnover of HK$8.22 million.\nThe increase follows the company's announcement of a strategic alliance with the premier global health investment and innovation platform, Deerfield Management. The partnership aims to co-develop a new generation of in vivo protein therapeutics and immunotherapies, while jointly advancing the global commercialization of collaborative pipeline products.\nUnder the agreement, Deerfield will engage in in-depth collaboration on the global clinical development and commercial expansion initiatives related to METIS TECHBIO-P's proprietary AI-powered nano-delivery platform, NanoForge, its driven solutions, and core pipeline projects. This includes a leading T-cell engager (TCE) project, discovered and advanced to the pre-clinical candidate (PCC) stage by the company's in-house AiProtein platform.\nDeerfield will further explore potential licensing and development opportunities for this project to facilitate its progression into IND-enabling studies and clinical development phases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.4","shortVersion":"4.42.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191305063","isCrawlerRequest":true}